BioMarin Pharmaceutical Bilan de santé
Santé financière contrôle des critères 6/6
BioMarin Pharmaceutical possède un total de capitaux propres de $5.4B et une dette totale de $594.6M, ce qui porte son ratio d'endettement à 11%. Son actif total et son passif total sont $6.9B et de $1.4B. L'EBIT de BioMarin Pharmaceutical est $326.4M ce qui fait que son ratio de couverture des intérêts -5.5. Elle dispose de liquidités et de placements à court terme de $930.4M.
Informations clés
11.0%
Ratio d'endettement
US$594.63m
Dette
| Ratio de couverture des intérêts | -5.5x |
| Argent liquide | US$930.44m |
| Fonds propres | US$5.41b |
| Total du passif | US$1.44b |
| Total des actifs | US$6.85b |
Mises à jour récentes de la santé financière
BioMarin Pharmaceutical (NASDAQ:BMRN) Seems To Use Debt Rather Sparingly
Sep 21
Is BioMarin Pharmaceutical (NASDAQ:BMRN) Using Too Much Debt?
Mar 30Is BioMarin Pharmaceutical (NASDAQ:BMRN) Using Too Much Debt?
Nov 03We Think BioMarin Pharmaceutical (NASDAQ:BMRN) Can Stay On Top Of Its Debt
Jul 18These 4 Measures Indicate That BioMarin Pharmaceutical (NASDAQ:BMRN) Is Using Debt Safely
Mar 27Recent updates
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Not Flying Under The Radar
Nov 14BioMarin Pharmaceutical (NASDAQ:BMRN) Seems To Use Debt Rather Sparingly
Sep 21BioMarin: Voxzogo Sales Surge Isn't Only Driving Force In 2024
Aug 21BioMarin Pharmaceutical: Steady Performer Scheduling Its Big Reveal In 09/2024
Jul 24An Intrinsic Calculation For BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Suggests It's 46% Undervalued
Jun 01BioMarin: Short-Term Headwinds But Long-Term Opportunities Remain
May 15Results: BioMarin Pharmaceutical Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Apr 26BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Shares Lagging The Industry But So Is The Business
Apr 21Is BioMarin Pharmaceutical (NASDAQ:BMRN) Using Too Much Debt?
Mar 30BioMarin Pharmaceutical: Still Has A Lot Of Room For Growth
Feb 29BioMarin's Growth Potential And Valuation: Is Now The Right Time To Invest?
Jan 19Little Excitement Around BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Revenues
Jan 05Is BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Trading At A 49% Discount?
Dec 15Is BioMarin Pharmaceutical (NASDAQ:BMRN) Using Too Much Debt?
Nov 03Is BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Trading At A 42% Discount?
Aug 09We Think BioMarin Pharmaceutical (NASDAQ:BMRN) Can Stay On Top Of Its Debt
Jul 18BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Could Be 42% Below Their Intrinsic Value Estimate
May 09Why Investors Shouldn't Be Surprised By BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Low P/S
Apr 18These 4 Measures Indicate That BioMarin Pharmaceutical (NASDAQ:BMRN) Is Using Debt Safely
Mar 27An Intrinsic Calculation For BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Suggests It's 39% Undervalued
Jan 09BioMarin redesigns organization, will lay off about 4% of its workforce
Oct 07BioMarin resubmits biologics license application to FDA for hemophilia A gene therapy
Sep 29BioMarin touts report on cost effectiveness of gene therapy Roctavian for hemophilia A
Sep 15BioMarin to resubmit hemophilia therapy for FDA approval after EU nod
Aug 25BioMarin may be an activist target after 13-F filings
Aug 15BioMarin (BMRN) boosts 2022 top and bottom line guidance on back of product sales growth
Aug 03BioMarin: More Growth
Jul 21BioMarin's Solid Pipeline Bears The First Fruit
Jun 27Analyse de la situation financière
Passif à court terme: Les actifs à court terme de BMRN ( $3.1B ) dépassent ses passifs à court terme ( $715.7M ).
Passif à long terme: Les actifs à court terme de BMRN ( $3.1B ) dépassent ses passifs à long terme ( $722.1M ).
Historique et analyse du ratio d'endettement
Niveau d'endettement: BMRN dispose de plus de liquidités que de sa dette totale.
Réduire la dette: Le ratio d'endettement de BMRN a été réduit de 27.4% à 11% au cours des 5 dernières années.
Couverture de la dette: La dette de BMRN est bien couverte par le flux de trésorerie opérationnel ( 69.7% ).
Couverture des intérêts: BMRN gagne plus d'intérêts qu'il n'en paie, donc la couverture des paiements d'intérêts n'est pas un problème.